Donor T-cell treatment after transplant for high-risk AML and MDS
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 6 months to 80 years
- You are planning or have had an allogeneic stem cell transplant (donor transplant)
- Your AML or MDS is “high-risk,” and you have not had a relapse in the blood/bone marrow
- Your strength/function score is at least 50 (Karnofsky/Lansky)
- T-cell “chimerism” levels are high (donor T cells make up enough of your body’s T cells)
- You must be able to give informed consent (or your parent/guardian can)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Hear when a new Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.